NHS patients to receive life-saving COVID-19 treatments
Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive treatments which can reduce the time spent in hospital by up to 10 days.
Results from the government-funded REMAP-CAP clinical trial also showed tocilizumab and sarilumab reduced the relative risk of death by 24%, when administered to patients within 24 hours of entering intensive care.
